Clinical Trials Arena on MSN4d
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase IIIAstraZeneca acquired the hypoparathyroidism therapy eneboparatide as part of a buyout of Amolyt Pharma in July 2024.
The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the ...
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
Topline data were announced from a phase 3 trial evaluating eneboparatide in adults with chronic hypoparathyroidism.
Alexion Pharmaceuticals’ ravulizumab for the prevention of delayed graft function after renal transplantation was granted FDA orphan ...
In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...
New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s ...
AstraZeneca has built its leading presence ... Also, the recent acquisition of Alexion looks like a solid strategic move done at a reasonable price. The Alexion addition brings in a rare drug ...
LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...
AstraZeneca added eneboparatide to the Alexion and AstraZeneca rare disease pipeline through the acquisition of Amolyt Pharma in July 2024, in a deal valued around $1.05bn. Shareholders received ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback